Publications by authors named "William K Oh"

100Publications

Treatment of muscle-invasive and advanced bladder cancer in 2020.

CA Cancer J Clin 2020 Aug 7. Epub 2020 Aug 7.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21631DOI Listing
August 2020

Lacrimal sac adenocarcinoma managed with androgen deprivation.

Am J Ophthalmol Case Rep 2020 Sep 24;19:100607. Epub 2020 Jul 24.

Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajoc.2020.100607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393461PMC
September 2020

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.

Prostate Cancer Prostatic Dis 2020 Apr 20. Epub 2020 Apr 20.

Department of Medicine, Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0231-5DOI Listing
April 2020

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Eur Urol 2020 04 27;77(4):508-547. Epub 2020 Jan 27.

University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.01.012DOI Listing
April 2020

The evolving landscape of immunotherapy in advanced prostate cancer.

Immunotherapy 2019 07 4;11(10):903-912. Epub 2019 Jun 4.

Department of Medicine, Division of Hematology & Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0019DOI Listing
July 2019

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.

J Immunother Cancer 2018 09 18;6(1):90. Epub 2018 Sep 18.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0408-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145108PMC
September 2018

Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.

J Urol 2018 12 4;200(6):1264-1272. Epub 2018 Aug 4.

American Urological Association Education and Research, Inc., Linthicum, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.07.090DOI Listing
December 2018

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.

Onco Targets Ther 2018 12;11:2141-2147. Epub 2018 Apr 12.

Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S147168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905496PMC
April 2018

First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?

J Clin Oncol 2018 04 12;36(11):1060-1061. Epub 2018 Feb 12.

Che-Kai Tsao and William K. Oh, Icahn School of Medicine at Mount Sinai, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4315DOI Listing
April 2018

Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey.

Clin Genitourin Cancer 2018 04 5;16(2):e411-e419. Epub 2017 Oct 5.

Carolina Urologic Research Center, Myrtle Beach, SC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.09.015DOI Listing
April 2018

Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer.

JCO Clin Cancer Inform 2017 11;1:1-12

Matthew D. Galsky, Nihal Mohamed, Charles Baker, Sumit Pokhriya, Jason Rogers, Ashish Atreja, Liangyuan Hu, Che-Kai Tsao, John Sfakianos, Reza Mehrazin, Nikhil Waingankar, William K. Oh, Madhu Mazumdar, and Bart S. Ferket, Icahn School of Medicine at Mount Sinai, New York; and Michael Diefenbach, Northwell Health, Great Neck, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874030PMC
November 2017

Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.

JCO Clin Cancer Inform 2017 11;1:1-10

Matthew D. Galsky, Mohamed Shahin, Rachel Jia, Kiev Gimpel-Tetra, Che-Kai Tsao, Charles Baker, Amanda Leiter, Reza Mehrazin, John P. Sfakianos, Patricia Acon, and William K. Oh, Icahn School of Medicine at Mount Sinai; John Holland, AMC Health; Tomasz Sablinski, Transparency Life Sciences, New York; and David R. Shaffer, Albany Medical Center, Albany, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/CCI.17.00044
Publisher Site
http://dx.doi.org/10.1200/CCI.17.00044DOI Listing
November 2017

Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.

Ther Adv Med Oncol 2017 Apr 14;9(4):287-298. Epub 2017 Feb 14.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834016687261
Publisher Site
http://dx.doi.org/10.1177/1758834016687261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405995PMC
April 2017

Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Nat Rev Clin Oncol 2017 05 22;14(5):269-283. Epub 2016 Nov 22.

Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 1470 Madison Avenue, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567685PMC
May 2017

Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.

Oncotarget 2016 10;7(42):68688-68707

The Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356583PMC
October 2016

Disease-specific classification using deconvoluted whole blood gene expression.

Sci Rep 2016 09 6;6:32976. Epub 2016 Sep 6.

Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, NY, 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep32976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011717PMC
September 2016

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.

Bladder Cancer 2016 Jul 27;2(3):341-349. Epub 2016 Jul 27.

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-160047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969712PMC
July 2016

The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer.

Bladder Cancer 2016 Jul 27;2(3):319-327. Epub 2016 Jul 27.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-160058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969695PMC
July 2016

Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.

Eur Urol 2016 11 12;70(5):707-708. Epub 2016 Jul 12.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.06.041DOI Listing
November 2016

Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.

J Clin Oncol 2016 08 6;34(22):2627-35. Epub 2016 Jun 6.

Matthew D. Galsky, John P. Sfakianos, Reza Mehrazin, Nihal Mohamed, Che-Kai Tsao, Paolo Boffetta, Peter Wiklund, William K. Oh, Madhu Mazumdar, and Bart Ferket, Icahn School of Medicine at Mount Sinai, New York; and Michael Diefenbach, Northwell Health, Great Neck, NY; Kristian Stensland, Lahey Clinic, Burlington, MA; and Peter Wiklund, Karolinska Institute, Stockholm Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012691PMC
August 2016

Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.

J Clin Oncol 2016 Mar 19;34(8):825-32. Epub 2016 Jan 19.

Matthew D. Galsky, Erin Moshier, Che-Kai Tsao, Martin Casey, Paolo Boffetta, and William K. Oh, Tisch Cancer Institute at Mount Sinai; Erin Moshier, John P. Sfakianos, Russell B. McBride, Paolo Boffetta, Madhu Mazumdar, and Juan P. Wisnivesky, Icahn School of Medicine at Mount Sinai, New York, NY; and Kristian D. Stensland, Lahey Clinic, Burlington, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.1076DOI Listing
March 2016

Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion.

Anticancer Drugs 2016 Mar;27(3):235-8

aDepartment of Pharmacy bDivision of Hematology/Oncology, The Tisch Cancer Institute, The Mount Sinai Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000321DOI Listing
March 2016

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.

Cancer Chemother Pharmacol 2015 Dec 13;76(6):1259-65. Epub 2015 Oct 13.

Genitourinary Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2884-7DOI Listing
December 2015

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Nat Rev Clin Oncol 2015 Jun 28;12(6):316-8. Epub 2015 Apr 28.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.79DOI Listing
June 2015

Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.

Curr Urol Rep 2015 Mar;16(3):13

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11934-015-0486-xDOI Listing
March 2015

Clinical trial awareness: Changes over time and sociodemographic disparities.

Clin Trials 2015 Jun 10;12(3):215-23. Epub 2015 Feb 10.

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774515571917DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667750PMC
June 2015

The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care.

J Urol 2015 Jul 23;194(1):36-41. Epub 2015 Jan 23.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.01.076DOI Listing
July 2015

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

J Urol 2015 Jul 24;194(1):91-7. Epub 2015 Jan 24.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.01.078DOI Listing
July 2015

Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Prostate 2015 May 5;75(6):616-27. Epub 2015 Jan 5.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.22945DOI Listing
May 2015

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Clin Genitourin Cancer 2015 Apr 22;13(2):113-23. Epub 2014 Oct 22.

Medical Oncology, Dana-Farber Cancer Institute and Internal Medicine, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418946PMC
April 2015

Geographic accessibility to clinical trials for advanced cancer in the United States.

JAMA Intern Med 2015 Feb;175(2):293-5

Divisions of General Internal Medicine and Pulmonary and Critical Care, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2014.6300DOI Listing
February 2015

Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.

Cancer 2014 Mar 30;120(6):833-9. Epub 2013 Dec 30.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28494DOI Listing
March 2014

Use of crowdsourcing for cancer clinical trial development.

J Natl Cancer Inst 2014 Oct 12;106(10). Epub 2014 Sep 12.

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju258DOI Listing
October 2014

Adult cancer clinical trials that fail to complete: an epidemic?

J Natl Cancer Inst 2014 Sep 4;106(9). Epub 2014 Sep 4.

Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju229DOI Listing
September 2014

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

BJU Int 2015 Jul 23;116(1):17-29. Epub 2014 Oct 23.

Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.12867
Publisher Site
http://dx.doi.org/10.1111/bju.12867DOI Listing
July 2015

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Sep 15;74(3):465-71. Epub 2014 Jul 15.

Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2518-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146643PMC
September 2014

Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.

Cancers (Basel) 2014 Jun 27;6(3):1298-327. Epub 2014 Jun 27.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers6031298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190542PMC
June 2014

Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.

Cancer 2014 Oct 25;120(19):2944-5. Epub 2014 Jun 25.

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28808DOI Listing
October 2014

The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer.

Ther Adv Urol 2014 Jun;6(3):97-104

Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287214528557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003844PMC
June 2014

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.

Asian J Androl 2014 May-Jun;16(3):331-3

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/1008-682X.127813DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023355PMC
December 2014

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

Clin Cancer Res 2014 Jun 10;20(12):3310-8. Epub 2014 Apr 10.

Authors' Affiliations: Division of Hematology and Oncology, Tisch Cancer Institute, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Statistical Innovations, Belmont; Department of Dermatology, Harvard Medical School, Boston, Massachusetts; Departments of Medicine, Dermatology and Translational Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and Gene News, Ontario, CanadaAuthors' Affiliations: Division of Hematology and Oncology, Tisch Cancer Institute, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Statistical Innovations, Belmont; Department of Dermatology, Harvard Medical School, Boston, Massachusetts; Departments of Medicine, Dermatology and Translational Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and Gene News, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2906DOI Listing
June 2014

Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.

Crit Rev Oncol Hematol 2014 Jun 2;90(3):253-61. Epub 2014 Feb 2.

Department of Medicine, Section of Hematology-Oncology, UAB Comprehensive Cancer Center, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.12.001DOI Listing
June 2014

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.

Eur Urol 2014 Aug 7;66(2):184-5. Epub 2014 Jan 7.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.12.061DOI Listing
August 2014

Adverse event reporting in cancer clinical trial publications.

J Clin Oncol 2014 Jan 9;32(2):83-9. Epub 2013 Dec 9.

Shanthi Sivendran, Lancaster General Health, Lancaster, PA; Asma Latif, Russell B. McBride, Kristian D. Stensland, Juan Wisnivesky, Lindsay Haines, William K. Oh, Matthew D. Galsky, Icahn School of Medicine at Mount Sinai, Mount Sinai, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.2219DOI Listing
January 2014

TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.

PLoS One 2013 15;8(10):e77366. Epub 2013 Oct 15.

Division of Hematology/Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077366PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797040PMC
June 2014

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

Urol Oncol 2014 Jan 18;32(1):48.e1-8. Epub 2013 Sep 18.

University of Athens, Athens, Greece; Hellenic Cooperative Oncology Group, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2013.07.001DOI Listing
January 2014

Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.

Lancet Oncol 2013 Jul 4;14(8):681-2. Epub 2013 Jun 4.

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70239-0DOI Listing
July 2013

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

Cancer 2013 Aug 29;119(16):3012-9. Epub 2013 May 29.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28146DOI Listing
August 2013

Metabolic complications with the use of mTOR inhibitors for cancer therapy.

Cancer Treat Rev 2014 Feb 16;40(1):190-6. Epub 2013 May 16.

Hematology/Oncology Medical Specialists, Lancaster General Health, Lancaster, PA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744486PMC
February 2014

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

Clin Genitourin Cancer 2013 Sep 11;11(3):346-52. Epub 2013 May 11.

Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.04.010DOI Listing
September 2013

Castration-resistant prostate cancer: AUA Guideline.

J Urol 2013 Aug 9;190(2):429-38. Epub 2013 May 9.

American Urological Association Education and Research, Inc., Linthicum, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2013.05.005DOI Listing
August 2013

New paradigms in microtubule-mediated endocrine signaling in prostate cancer.

Mol Cancer Ther 2013 May 1;12(5):555-66. Epub 2013 May 1.

Division of Hematology-Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0871DOI Listing
May 2013

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

Expert Opin Drug Metab Toxicol 2013 Jul 12;9(7):835-46. Epub 2013 Apr 12.

The Tisch Cancer Institute, Mount Sinai School of Medicine, Division of Hematology and Medical Oncology, 1 Gustave L Levy Place, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2013.789019DOI Listing
July 2013

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Urol Oncol 2014 Jan 18;32(1):30.e15-21. Epub 2013 Feb 18.

University of Athens & Hellenic Cooperative Oncology Group, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2012.11.001DOI Listing
January 2014

Emerging personalized approaches for the management of advanced urothelial carcinoma.

Expert Rev Anticancer Ther 2012 Dec;12(12):1537-43

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744482PMC
December 2012

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

J Natl Cancer Inst 2012 Dec 23;104(23):1837-40. Epub 2012 Oct 23.

Division of Hematology/Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, Mount Sinai School of Medicine, 1 Gustave L Levy Pl, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/104/23/1837.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djs435
Publisher Site
http://dx.doi.org/10.1093/jnci/djs435DOI Listing
December 2012

Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.

Nat Rev Clin Oncol 2012 Nov 9;9(11):613-4. Epub 2012 Oct 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.181DOI Listing
November 2012

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

BJU Int 2012 Dec 18;110(11):1580-8. Epub 2012 Sep 18.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1464-410X.2012.11445.x
Publisher Site
http://dx.doi.org/10.1111/j.1464-410X.2012.11445.xDOI Listing
December 2012

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

BJU Int 2012 Dec 29;110(11):1729-35. Epub 2012 Aug 29.

Lank Center for Genitourinary Oncology, Department of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2012.11456.xDOI Listing
December 2012

Atypical metastases from prostate cancer: 10-year experience at a single institution.

AJR Am J Roentgenol 2012 Aug;199(2):367-72

Department of Imaging, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.11.7533DOI Listing
August 2012

Bevacizumab treatment of prostate cancer.

Expert Opin Biol Ther 2012 Sep 9;12(9):1241-9. Epub 2012 Jul 9.

Mount Sinai School of Medicine, Division of Hematology and Medical Oncology , 1 Gustave L Levy Place, Box 1128, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2012.704015DOI Listing
September 2012

Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.

Cancer 2012 Dec 15;118(23):5947-54. Epub 2012 Jun 15.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27658DOI Listing
December 2012

Trends in the use of cytoreductive nephrectomy in the United States.

Clin Genitourin Cancer 2012 Sep 30;10(3):159-63. Epub 2012 May 30.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2012.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744481PMC
September 2012

Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.

Cancer Treat Rev 2012 Nov 30;38(7):919-25. Epub 2012 May 30.

Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, United States.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573721200110
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2012.05.001DOI Listing
November 2012

Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.

World J Urol 2013 Oct 24;31(5):1211-7. Epub 2012 May 24.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY, 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-012-0873-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744479PMC
October 2013

The emerging role of circulating tumor cell detection in genitourinary cancer.

J Urol 2012 Jul 12;188(1):21-6. Epub 2012 May 12.

Division of Hematology/Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2012.02.2558DOI Listing
July 2012

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.

CA Cancer J Clin 2012 Sep-Oct;62(5):299-308. Epub 2012 Apr 24.

Division of Hematology and Medical Oncology, Department of Medicine, Director of Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21141DOI Listing
January 2013

Overcoming castration resistance in prostate cancer.

Curr Opin Urol 2012 May;22(3):167-74

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0b013e3283523b8bDOI Listing
May 2012